Pro Feature
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moGLYCEROL PHENYLBUTYRATE (glycerol phenylbutyrate oral) by Pfizer is (nh 3 , nh 4 ). Approved for acute hyperammonemia in patients with ucds because more rapidly acting interventions are essential to reduce plasma ammonia levels, acute hyperammonemia in patients with ucds. First approved in 2021.
Drug data last refreshed 18h ago
(NH 3 , NH 4 ). Absence of these enzymes or transporters results in the accumulation of toxic levels of ammonia in the blood and brain of affected patients. Glycerol phenylbutyrate is a triglyceride containing 3 molecules of PBA. PAA, the major metabolite of PBA, is the active moiety of glycerol…
Worked on GLYCEROL PHENYLBUTYRATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo